Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020116573 - METHOD FOR DETERMINING PROGNOSIS OF ENDOMETRIAL CANCER

Publication Number WO/2020/116573
Publication Date 11.06.2020
International Application No. PCT/JP2019/047656
International Filing Date 05.12.2019
IPC
C12Q 1/04 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/68 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Applicants
  • 学校法人慶應義塾 KEIO UNIVERSITY [JP]/[JP]
  • 積水メディカル株式会社 SEKISUI MEDICAL CO., LTD. [JP]/[JP]
Inventors
  • 金井 弥栄 KANAI, Yae
  • 新井 恵吏 ARAI, Eri
  • 青木 大輔 AOKI, Daisuke
  • 進 伸幸 SUSUMU, Nobuyuki
  • 山上 亘 YAMAGAMI, Wataru
  • 真壁 健 MAKABE, Takeshi
Agents
  • 特許業務法人アルガ特許事務所 THE PATENT CORPORATE BODY ARUGA PATENT OFFICE
Priority Data
2018-22827605.12.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) METHOD FOR DETERMINING PROGNOSIS OF ENDOMETRIAL CANCER
(FR) MÉTHODE POUR DÉTERMINER LE PRONOSTIC D'UN CANCER DE L'ENDOMÈTRE
(JA) 子宮体癌の予後の判定方法
Abstract
(EN)
The present invention pertains to a method for determining the prognosis of endometrial cancer, a method for determining suitability of an endometrial cancer patient with respect to conservation treatment, and a method for determining the risk of endometrial cancer. These methods include detecting the level of DNA methylation at target CpG sites in genomic DNA derived from endometrial cells, endometrial cancer cells, or tissue including these cells. From the detected DNA methylation level, the prognosis of endometrial cancer, the suitability to conservation treatment, or the risk of endometrial cancer is determined for a subject.
(FR)
Procédé pour déterminer le pronostic d'un cancer de l'endomètre, procédé pour déterminer l'adéquation d'un patient atteint d'un cancer de l'endomètre par rapport à un traitement de conservation, et procédé pour déterminer le risque de cancer de l'endomètre. Ces procédés comprennent la détection du niveau de méthylation d'ADN au niveau de sites CpG cibles dans l'ADN génomique dérivé de cellules endométriales, de cellules cancéreuses endométriales, ou de tissu comprenant lesdites cellules. A partir du niveau de méthylation d'ADN détecté, le pronostic du cancer de l'endomètre, l'adéquation d'un traitement avec conservation, ou le risque de cancer de l'endomètre est déterminé pour un sujet.
(JA)
子宮体癌の予後判定方法、温存療法に対して適合性である子宮体癌患者の判定方法、及び子宮体癌のリスク判定方法。当該方法は、子宮内膜細胞、子宮体癌細胞又はそれらを含む組織由来のゲノムDNAにおける標的CpGサイトのDNAメチル化レベルを検出することを含む。検出したDNAメチル化レベルから、被験体についての子宮体癌の予後、温存療法への適合性、又は子宮体癌のリスクが判定される。
Latest bibliographic data on file with the International Bureau